Angiogenesis inhibitors, study factors to limitations, solutions A new generation of cancer medicines designed to starve tumors of their blood circulation – called angiogenesis inhibitors -succeeds initially, but then promotes even more invasive cancer growth-sometimes with an increased incidence of metastases, according to a new study in animals. The study clarifies similar findings in other animal research and is in keeping with some early proof from a small number of scientific trials with cancer patients www.sildalis.org . People have thought that angiogenesis-inhibiting therapy should hinder metastasis, but these studies show this is not necessarily the case, says Gabriele Bergers, PhD, co-writer of a paper reporting the study in the March 3, 2009 problem of the journal Malignancy Cell.
Related StoriesHigh blood circulation pressure, smoking, and poor dietary practices are greatest risk elements for deathStudy backs more aggressive blood circulation pressure treatment, says ACC President Kim Allan WilliamsHaving high blood pressure in midlife make a difference cognition a long time laterNicolas Danchin, M.D., F.E.S.C., Htpital Europien Georges Pompidou, Paris, and co-workers analyzed seven previous randomized and managed trials of ACE inhibitors in sufferers with coronary artery disease. The studies examined five different ACE inhibitors and included a complete of 33,960 sufferers, who were implemented for a minimum of two years and typically 4.4 years.